JCA readiness: How to prepare for success in the new EU HTA system
Author: Prof. Matthias P. Schönermark, MD, PhD, Chief Strategy Officer JCA readiness: How to prepare for success in the […]
Insights
New Government in Germany – What the Coalition Agreement Means for Germany as a Pharma Hub
Author: Florian Stieglitz, Consultant, Germany New Government in Germany – What the Coalition Agreement Means for Germany as a Pharma
Publication: Market Access Under Agile Conditions – An Update on the Agile German AMNOG Dossier
Authors: Kielhorn-Schönermark, H., Zavatta, E., Sake, S., Hantke, I. Summary: Market access in Germany is and remains one of the
Repurposed Drugs Launched Under the AMNOG in Germany
Effects on Benefit Assessment and Price Development Authors: Sake SM, Martyniszyn-Eiben A, Zavatta E, Glüsen M, Berger I, Schönermark M
From Vague to Valid – Chances and Risks of Benefit Re-Assessments Due to New Scientific Evidence in Germany
Chances and Risks of Benefit Re-Assessments Due to New Scientific Evidence in Germany Authors: Schwerdtfeger V, Hantke I, Schönermark M
German National Strategy for Gene and Cell Therapies (GCT) Handed Over
Starting signal for a solution-orientated concept for Germany. In June 2024, the National Strategy for Gene and Cell Therapies (GCT)
Patient Reported Outcome Measures (PROM) in Germany
PROM Are of Profound Importance for the Success of Health Technology Assessments in Oncologic Indications in Germany Authors: Brand D,
Outcomes of Benefit Assessments of Orphan Drugs Without Orphan Designation in Germany
Outcomes of Benefit Assessments of Orphan Drugs Without Orphan Designation in Germany Authors: Frick L, Qiu Z, Schönermark M. Objectives:
Combination discount in Germany – a bureaucratic monster
Author: Lukas Heinrich Schoppmeyer, Consultant, Germany Implementation regulation of the combination discount according to section 130e SGB V named by the
The 2nd Joint Scientific Consultation request period 2025 – a unique opportunity?
Author: Sebastian Vinzens, Senior Medical Writer, Germany Joint Scientific Consultations (JSCs) are primarily designed to provide critical input into
